Scandinavian journal of rheumatology
-
Scand. J. Rheumatol. · Jul 2005
Randomized Controlled Trial Comparative Study Clinical TrialA powder made from seeds and shells of a rose-hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial.
The aim of this study was to determine whether a herbal remedy made from a subspecies of rose-hip (Rosa canina) might reduce symptoms of osteoarthritis and consumption of rescue medication in patients suffering from osteoarthritis. ⋯ The data suggest that the present herbal remedy can alleviate symptoms of osteoarthritis and reduce the consumption of 'rescue medication'.
-
In this review on the genetic aspects of rheumatic diseases, the approach was taken (i) to discuss, in general, important principles in the identification of susceptibility genes and (ii) to focus on five autoimmune rheumatic diseases that have the characteristics of complex diseases and in which important advances have been made in the identification of the genetic component. A decade ago, most reviews on the genetics of rheumatic diseases focused almost exclusively on a discussion of the human leukocyte antigen (HLA) but in this fast-moving field it is now apparent that genes outside the HLA also contribute to susceptibility. Current hypotheses concerning the pathogenesis of autoimmunity have led to the inclusion of hundreds of genes as potential candidates. ⋯ The identification of the genes involved in complex diseases will contribute to an understanding of disease mechanisms and disease biology. The disease pathways by which the genes exert their effects or functions could lead to the discovery of new therapeutic targets that may be modulated. An increased understanding of the interactions between genes and environment might also be attained.
-
Scand. J. Rheumatol. · Jan 2005
Editorial Historical ArticleScandinavian Journal of Rheumatology 1955-2005: development and state of the Journal on its 50th anniversary.
The Scandinavian Society for Rheumatology was founded in Copenhagen in September 1946 and is still actively stimulating cooperation among rheumatologists in the Scandinavian countries by organising biannual Scandinavian congresses, and by circulating an international scientific publication, the Scandinavian Journal of Rheumatology, now celebrating its 50th anniversary. We hope that the newly implementation of web-based submission of manuscripts and peer reviewing, together with the new cover and change in the Journal's contents, will be of benefit to our authors, reviewers, and readers. At the Editorial Office we express our hope for a continuous and fruitful collaboration with the many people involved in the Scandinavian Journal of Rheumatology. Our thanks are due to those who made it possible over the past 50 years to publish a journal of high scientific quality within the field of rheumatology.
-
Scand. J. Rheumatol. · Jan 2004
Randomized Controlled Trial Multicenter Study Clinical TrialRapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate.
This randomized, placebo-controlled, double-blind, Phase 1 study assessed the magnitude, onset, and duration of response with intravenous (i.v.) and subcutaneous (s.c.) adalimumab (Humira, Abbott Laboratories) combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) despite previous MTX therapy. ⋯ Either i.v. or s.c. adalimumab added to MTX significantly improved the signs and symptoms of RA compared with MTX alone. Subcutaneously administered adalimumab appeared to provide a response that was as great, as rapid, and as enduring as that with i.v. adalimumab.
-
Scand. J. Rheumatol. · Jan 2004
ReviewThe genetic background of tumour necrosis factor receptor-associated periodic syndrome and other systemic autoinflammatory disorders.
Systemic autoinflammatory disorders are hereditary diseases with symptoms of acute inflammation and a rise in serum acute phase proteins as a consequence, but with no signs of autoimmunity. By the end of the 1990s, four types of hereditary periodic fever had been described in the medical literature: familial Mediterranean fever, hyperimmunoglobulinemia D with periodic fever syndrome (HIDS), tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS) and Muckle-Wells syndrome. ⋯ In patients of Nordic descent, cases of HIDS and TRAPS have been reported. We provide an overview of the genetic background and main clinical aspects of the different autoinflammatory disorders, with an emphasis on TRAPS.